• Events
    • Future Meetings
    • Digital Events
    • EURETINA 2022 Hamburg
      • Browse Programme
      • Registration Information
      • Hotel Bookings
    • EURETINA 2021 Virtual
      • 2021 Virtual Sessions On-Demand (Members Only)
      • Programme
      • Satellite Symposia
      • Sponsors
  • Free Resources
    • Webinars
    • Podcasts
    • 2021 Virtual Session Abstracts
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • Mentorship Programme 2022/23
    • RMCR grant programme
    • Observership Grant Programme
    • Women in Retina
    • YOURS
    • CME Credits
  • Member Login
Menu
  • Events
    • Future Meetings
    • Digital Events
    • EURETINA 2022 Hamburg
      • Browse Programme
      • Registration Information
      • Hotel Bookings
    • EURETINA 2021 Virtual
      • 2021 Virtual Sessions On-Demand (Members Only)
      • Programme
      • Satellite Symposia
      • Sponsors
  • Free Resources
    • Webinars
    • Podcasts
    • 2021 Virtual Session Abstracts
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • Mentorship Programme 2022/23
    • RMCR grant programme
    • Observership Grant Programme
    • Women in Retina
    • YOURS
    • CME Credits
  • Member Login
  • October 12, 2021
  • Author: EURETINA

Using artificial intelligence to predict injection frequency

Artificial intelligence and machine learning-based approaches are increasingly finding their way into everyday clinical practice. They may prove helpful in predicting future treatment intervals in the management of patients with neovascular AMD, according to Maximilian Pfau MD,  who presented his research at the EURETINA 2021 Virtual Congress.

“Our study showed that anti-VEGF therapy demand in choroidal neovascularization (CNV) due to AMD can be predicted with reasonable accuracy and achieve the same prediction as classical machine learning-based models. The advantage of this approach is that it can help physicians consider the model output thoughtfully or use standard treatment as a fallback alternative,” he said.

Using such AI models may help physicians select patients for whom long-term treatment options beyond conventional anti-VEGF injections may provide a favourable risk/benefit ratio, added Dr Pfau.

In the study carried out at the University of Bonn, Dr Pfau and co-workers conducted a retrospective analysis of 138 visits of 99 eyes with neovascular AMD using scans from two clinical centres.

The team extracted 270 spectral-domain-OCT-based features using deep learning-based AI segmentation. Retinal thickness and reflectivity values were extracted for the central and the four inner Early Treatment Diabetic Retinopathy Study (ETDRS) subfields for six retinal layers. Machine-learning models were probed to predict the anti-VEGF treatment frequency within the next 12 months.

Probabilistic forecasting was performed using natural gradient boosting (NGBoost), which outputs a full probability distribution. The primary outcome measure was the mean absolute error (MAE) between the predicted versus actual anti-VEGF treatment frequency.

In terms of results, the prediction of future anti-VEGF treatment frequency was observed with an accuracy of 2.60 injections per year using random forest regression and 2.66 injections per year using NGBoost. The prediction intervals were well calibrated and reflected the genuine uncertainty of NGBoost-based predictions, said Dr Pfau.

Unlike classic point prediction, which determines how many injections are required for each patient, probabilistic forecasting includes an estimate of each prediction’s uncertainty, explained Dr Pfau.

With this knowledge, predictions with high certainty would allow physicians to use the prediction for clinical decision-making about upcoming anti-VEGF therapy approaches. On the other hand, uncertain predictions would enable them to opt for a manual fallback alternative such as conventional PRN or treat-and-extend protocol with established anti-VEGF agents.

Responding to a question concerning the possibility of using the AI model to predict beyond a 12-month window, Dr Pfau said that while it was technically possible to do so, the model would need much larger data sets to reduce uncertainty in its predictions.

Going forward, Dr Pfau said that future work would focus on validating the uncertainty estimates for NGBoost to ensure they truly highlight out-of-distribution samples, especially in conjunction with external data sets.

END

Contact: [email protected]

PrevPrevious
NextNext

You might also like

Apellis International: The Future of Geographic Atrophy: advancing diagnosis, treatment and management

Read More

ZEISS: Fine-Tune your Vitreoretinal Surgery – How to get the best view for you and your patients

Read More

Canon Medical Systems Europe: Wide field swept source OCT: Learn from our experts!

Read More

Meet the Keynote Speakers

Keynote Speaker - Sobha Sivaprasad
Euretina Lecture with Sobha Sivaprasad
Opthalmologica Lecture with Enrico Borrelli
Ophthalmologica Lecture with Enrico Borrelli
Gisbert Richard Lecture with Catherine Creuzot-Garcher
Gisbert Richard Lecture with Catherine Creuzot-Garcher
Kreissig Award Lecture with Hiroko Terasaki
Kreissig Award Lecture with Hiroko Terasaki

Secretariat Address
European Society of Retina Specialists
Ground Floor, The Apex Building 
Blackthorn Road
Sandyford Business Park
Co Dublin, D18 H6K2

Phone:+353 1 2100092
Email: [email protected]

EURETINA 2022 Hamburg

Opportunities

Memberships

Forum

About

Privacy Policy

Newsletter Sign up

By clicking 'Subscribe', you agree to the terms of our Privacy Policy. 
 
 

Follow us

© EURETINA 2021 All rights reserved
  • Events
    • Future Meetings
    • Digital Events
    • EURETINA 2022 Hamburg
      • Browse Programme
      • Registration Information
      • Hotel Bookings
    • EURETINA 2021 Virtual
      • 2021 Virtual Sessions On-Demand (Members Only)
      • Programme
      • Satellite Symposia
      • Sponsors
  • Free Resources
    • Webinars
    • Podcasts
    • 2021 Virtual Session Abstracts
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • Mentorship Programme 2022/23
    • RMCR grant programme
    • Observership Grant Programme
    • Women in Retina
    • YOURS
    • CME Credits
  • Member Login